Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.750
-0.050 (-2.78%)
Dec 20, 2024, 4:00 PM EST - Market closed
Palisade Bio Revenue
In the year 2023, Palisade Bio had annual revenue of $250.00K.
Revenue (ttm)
$250.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
2.33M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Venus Concept | 67.20M |
Xylo Technologies | 57.64M |
Molecular Templates | 25.47M |
NovaBay Pharmaceuticals | 13.84M |
Avinger | 7.26M |
Fresh2 Group | 2.34M |
Biodexa Pharmaceuticals | 104.90K |
PALI News
- 4 days ago - Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewsWire
- 8 days ago - Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewsWire
- 9 days ago - What's Going On With Palisade Bio Stock On Thursday? - Benzinga
- 9 days ago - Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewsWire
- 18 days ago - Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewsWire
- 4 weeks ago - Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) - GlobeNewsWire
- 5 weeks ago - Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire